| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Adar Yaacov, Gregory Lazarian, Tatjana Pandzic, Simone Weström, Panagiotis Baliakas, Samia Imache, Valérie Lefebvre, Florence Cymbalista, Fanny Baran-Marszak, Shai Rosenberg, Thierry Souss. Cancer associated variant enrichment CAVE, a gene agnostic approach to identify low burden variants in chronic lymphocytic leukemia. Scientific reports. vol 14. issue 1. 2024-09-20. PMID:39304718. |
indeed, as tp53 mutations are part of treatment decision-making algorithms and low-burden variants are frequent, there is a need to distinguish true variants from background noise. |
2024-09-20 |
2024-09-23 |
Not clear |
| Maria Julia Montoro, Laura Palomo, Claudia Haferlach, Pamela Acha, Onyee Chan, Víctor Navarro, Yasuo Kubota, Felicitas Isabel Schulz, Manja Meggendorfer, Robert Briski, Najla Al-Ali, Blanca Xicoy, Felix Lopez, Francesc Bosch, Teresa González, Lea Naomi Eder, Andrés Jerez, Yu-Hung Hung Wang, Alessia Campagna, Valeria Santini, Teresa Bernal Del Castillo, Esperanza Such, Hwei-Fang Tien, Nicolás Díaz Varela, Uwe Platzbecker, Detlef Thomas Haase, María Díez-Campelo, Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Daniel Howard Wiseman, Ulrich Germing, Jaroslaw P Maciejewski, Rami S Komrokji, Francesc Sole, Torsten Haferlach, David Valcárce. Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion. Blood. 2024-07-29. PMID:39074355. |
this study underscores the importance of considering tp53 allelic state and vaf in the risk stratification and treatment decision-making process for patients with mds-del(5q). |
2024-07-29 |
2024-08-02 |
Not clear |
| Jitka Malcikova, Sarka Pavlova, Panagiotis Baliakas, Thomas Chatzikonstantinou, Eugen Tausch, Mark Catherwood, Davide Rossi, Thierry Soussi, Boris Tichy, Arnon P Kater, Carsten U Niemann, Frederic Davi, Gianluca Gaidano, Stephan Stilgenbauer, Richard Rosenquist, Kostas Stamatopoulos, Paolo Ghia, Sarka Pospisilov. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update. Leukemia. 2024-05-16. PMID:38755420. |
in chronic lymphocytic leukemia (cll), analysis of tp53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. |
2024-05-16 |
2024-05-27 |
Not clear |
| Joanna Moes-Sosnowska, Adam Szpechcinski, Joanna Chorostowska-Wynimk. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2023-10-16. PMID:37840519. |
since the presence of tp53 mutations in nsclc has been linked to its decreased responsiveness to egfr, alk, and ros1 targeted therapy in most of the referenced studies, the review also discusses the impact of tp53 mutations on treatment resistance.it seems plausible that assessing the tp53 mutation status could aid in patient stratification for optimal clinical decision-making. |
2023-10-16 |
2023-11-08 |
Not clear |
| Federica Pezzuto, Véronique Hofman, Christophe Bontoux, Francesco Fortarezza, Francesca Lunardi, Fiorella Calabrese, Paul Hofma. The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies? Lung cancer (Amsterdam, Netherlands). vol 181. 2023-05-27. PMID:37244040. |
the study provides a deeper understanding of the mechanisms underlying the variability of the genetic landscape of egfr-mutated nsclc and summarizes notably the clinical importance of tp53 co-mutations for an open avenue to more properly addressing the clinical decision-making in the near future. |
2023-05-27 |
2023-08-14 |
Not clear |
| Nana Matsumoto, Padmini Manrai, Douglas Rottmann, Xinyu Wu, Hisham Assem, Pei Hui, Natalia Buz. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2023-02-02. PMID:36730675. |
our results further support that p53 ihc can serve as an accurate predictor of tp53 alterations in ecs to aid the molecular-based tumor classification and the distinction between tumor histotypes, both of which play an important role in the assessment of clinical prognosis and therapeutic decision making. |
2023-02-02 |
2023-08-14 |
Not clear |
| Jitka Malcikova, Sarka Pavlova, Barbara Kunt Vonkova, Lenka Radova, Karla Plevova, Jana Kotaskova, Karol Pal, Barbara Dvorackova, Marcela Zenatova, Jakub Hynst, Eva Ondrouskova, Anna Panovska, Yvona Brychtova, Kristyna Zavacka, Boris Tichy, Nikola Tom, Jiri Mayer, Michael Doubek, Sarka Pospisilov. Low-burden TP53 mutations in CLL: Clinical impact and clonal evolution within the context of different treatment options. Blood. 2021-11-17. PMID:33945616. |
altogether, our data support the incorporation of low-burden tp53 variants in clinical decision-making. |
2021-11-17 |
2023-08-13 |
Not clear |
| Yibulayin Xiayimaierdan, P Song, S G Ga. [The influence of TP53 mutation on the therapeutic effect of EGFR tyrosine kinase inhibitor and prognosis of EGFR mutant non-small cell lung cancer patients]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. vol 42. issue 1. 2020-02-17. PMID:32023774. |
however, in the current clinical practice, tp53 mutation is not a key factor of therapeutic decision-making, so further studies are needed to clarify the impact of tp53 mutation (including each subtype) on the potential benefits of egfr-targeted therapy of nsclc. |
2020-02-17 |
2023-08-13 |
Not clear |
| Shinsuke Hirabayashi, Suzuki Misato, Atsushi Manab. [TP53 mutations and hematological malignancies]. [Rinsho ketsueki] The Japanese journal of clinical hematology. vol 59. issue 11. 2019-05-07. PMID:30531145. |
tp53 mutations affect the prognosis and therapeutic decision-making. |
2019-05-07 |
2023-08-13 |
human |
| Kanaga Sabapathy, David P Lan. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nature reviews. Clinical oncology. vol 15. issue 1. 2017-12-20. PMID:28948977. |
the utility of this knowledge of tp53 mutations in developing selective therapeutic options, and in facilitating clinical decision-making is discussed. |
2017-12-20 |
2023-08-13 |
Not clear |
| Melissa A Alderfer, Kristin Zelley, Robert B Lindell, Ana Novokmet, Phuong L Mai, Judy E Garber, Deepika Nathan, Sarah Scollon, Nicolette M Chun, Andrea F Patenaude, James M Ford, Sharon E Plon, Joshua D Schiffman, Lisa R Diller, Sharon A Savage, David Malkin, Carol A Ford, Kim E Nichol. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. vol 121. issue 2. 2015-03-09. PMID:25223899. |
parent decision-making around the genetic testing of children for germline tp53 mutations. |
2015-03-09 |
2023-08-13 |
Not clear |
| Melissa A Alderfer, Kristin Zelley, Robert B Lindell, Ana Novokmet, Phuong L Mai, Judy E Garber, Deepika Nathan, Sarah Scollon, Nicolette M Chun, Andrea F Patenaude, James M Ford, Sharon E Plon, Joshua D Schiffman, Lisa R Diller, Sharon A Savage, David Malkin, Carol A Ford, Kim E Nichol. Parent decision-making around the genetic testing of children for germline TP53 mutations. Cancer. vol 121. issue 2. 2015-03-09. PMID:25223899. |
the benefits of tp53 mutation testing of children are a matter of debate and knowledge of parent decision-making around such testing is limited. |
2015-03-09 |
2023-08-13 |
Not clear |
| Federica Perrone, Paolo Bossi, Barbara Cortelazzi, Laura Locati, Pasquale Quattrone, Marco A Pierotti, Silvana Pilotti, Lisa Licitr. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. vol 28. issue 5. 2010-03-04. PMID:20048189. |
purpose to find out if tp53 functional status predicts response to neoadjuvant chemotherapy and thus may be helpful during treatment decision making of oral cavity squamous cell carcinoma (scc) patients. |
2010-03-04 |
2023-08-12 |
Not clear |